Analysts Anticipate NewLink Genetics Corporation (NASDAQ:NLNK) Will Announce Quarterly Sales of $2.38 Million
Analysts expect that NewLink Genetics Corporation (NASDAQ:NLNK) will report $2.38 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for NewLink Genetics Corporation’s earnings, with the highest sales estimate coming in at $5.00 million and the lowest estimate coming in at $300,000.00. NewLink Genetics Corporation posted sales of $15.35 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 84.5%. The firm is expected to announce its next earnings report on Tuesday, November 7th.
According to Zacks, analysts expect that NewLink Genetics Corporation will report full year sales of $2.38 million for the current fiscal year, with estimates ranging from $13.13 million to $23.10 million. For the next fiscal year, analysts expect that the business will post sales of $12.20 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for NewLink Genetics Corporation.
NewLink Genetics Corporation (NASDAQ:NLNK) last announced its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. The firm had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%.
NLNK has been the topic of several recent research reports. Cantor Fitzgerald set a $32.00 target price on NewLink Genetics Corporation and gave the stock a “buy” rating in a research report on Thursday, May 4th. Robert W. Baird reiterated an “outperform” rating and issued a $25.00 price objective on shares of NewLink Genetics Corporation in a research report on Monday, June 5th. ValuEngine upgraded NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research report on Friday, May 19th. Zacks Investment Research downgraded NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $18.00 price objective on shares of NewLink Genetics Corporation in a research report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $18.17.
Several large investors have recently modified their holdings of the company. Columbus Circle Investors increased its stake in shares of NewLink Genetics Corporation by 72.5% in the second quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock worth $4,349,000 after buying an additional 248,724 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $5,127,000. EAM Investors LLC acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $4,622,000. Ameriprise Financial Inc. acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $3,453,000. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $2,578,000. Institutional investors own 51.48% of the company’s stock.
NewLink Genetics Corporation (NASDAQ NLNK) opened at 6.53 on Friday. The firm has a 50-day moving average price of $7.31 and a 200 day moving average price of $13.61. NewLink Genetics Corporation has a one year low of $5.90 and a one year high of $25.17. The firm’s market capitalization is $192.12 million.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.